Key highlights from a descriptive analysis of the POLARIX trial

During the 17th ICML, the Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, Montpellier, FR. We asked, What are the key...

SWOG S1826: Nivolumab-AVD vs brentuximab vedotin-AVD in patients with newly diagnosed advanced-stage cHL

Here, we summarize the latest results from the phase III SWOG S1826 trial investigating...

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?

During the 17th ICML, the Lymphoma Hub spoke to Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR....

Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL

During the 17th International Conference on Malignant Lymphoma, the Lymphoma Hub spoke to Georg Lenz, Münster University Hospital, Münster,...

Epcoritamab receives approval from EC and Japan Ministry of Health, Labour and Welfare for R/R LBCL

Epcoritimab has received approval from the European Commission and Ministry of Health, Labour and...

Impact of bridging therapy on CAR T-cell outcomes in patients with LBCL

Here, we summarize the outcomes of bridging therapy in patients with R/R LBCL undergoing axi-cel or tisa-cel CAR T-cell therapy.

SLS009 exhibits favorable data in R/R lymphomas: topline results from phase I dose escalation trial.

Primary and secondary endpoints were met in a phase I dose escalation study of SLS009 in patients...

KEYNOTE-087: 5-year follow-up data of pembrolizumab in R/R classic Hodgkin lymphoma

Here, we summarize key findings of the 5-year safety and efficacy of pembrolizumab in patients with relapsed or...

IRENE-G: A prospective RCT of nutritional support following allo-HSCT

The Lymphoma Hub is pleased to summarize the design and rationale of the IRENE-G trial (NCT05111834; Impact of Resistance Exercise...

What supportive care is needed for patients receiving CAR T-cell therapy?

During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Natacha Bolaños, Lymphoma Coalition,...

Educational theme | Targeted treatment for elderly patients with CLL

This article addresses the suitability of targeted agents in older patients with CLL by summarizing a recent publication that...

Educational theme | Disease management of elderly patients with aggressive B-cell lymphoma in the modern era

Lymphoma Hub recently shared a brief insight on how to improve care for the elderly...

When and how should treatment be modified for older patients with HL?

During the ISHL 2022 meeting, the Lymphoma Hub spoke with Astrid Pavlovsky, Fundaleu, Buenos Aires, AR. We asked, When and how...

What does data from the Brazilian Prospective HL Registry tell us about outcomes for older patients?

Biasoli describes the Brazilian Prospective Hodgkin Lymphoma Registry and comments on the...